• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside enrolls first patient in phase III trial of Zuprata combination therapy

February 16, 2017 By Sarah Faulkner

Clearside enrolls first patient in phase III trial of Zuprata combination therapyClearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in a phase III trial evaluating Zuprata, its suspension formulation of triamcinolone acetonide, in combination with Eylea, intravitreal aflibercept, for the treatment of macular edema associated with retinal vein occlusion.

The trial is slated to enroll 460 patients with retinal vein occulsion to assess the efficacy and safety of the combination therapy. In 1 arm of the study, patients will receive the combination therapy at the beginning of the trial, intravitreal Eylea at week 4 and the combination therapy again at weeks 12 and 24. Patients in the control arm will receive intravitreal Eylea alone every 4 weeks until week 24, the company reported.

Researchers will follow up with the patients for 6 months after 24 weeks of treatment, according to Clearside. The trial’s primary objective is to determine the proportion of patients in each group with the best corrected visual acuity improvement of at 8 weeks following initial treatment.

Investigators will also evaluate secondary efficacy and safety endpoints, Clearside said.

“This patient’s enrollment represents another significant milestone in our Zuprata development program,” CEO & president Daniel White said in prepared remarks. “Based on the visual acuity improvements and macular edema reductions observed in its previous Phase 2 TANZANITE trial, we believe the SAPPHIRE study has the potential to demonstrate that the addition of Zuprata to Eylea treatment may offer an earlier opportunity for improved vision and reduction of macular edema over Eylea treatment alone.  We believe that when Zuprata is used together with intravitreal Eylea in RVO patients, it has the potential to provide similar vision results with fewer injections.”

In November last year, Clearside enrolled the 1st patient in clinical trial of Zuprata and intravitreal aflibercept, Eylea, for the treatment of diabetic macular edema.

The Alpharetta, Ga.-based company’s Hulk Phase I/II trial is an open-label, multi-center study designed to evaluate the safety and efficacy Zuprata administered in the suprachoroidal space along with intravitreal aflibercept and as an independent therapy in patients with diabetic macular edema. The trial is slated to enroll 20 patients with equal participation in both arms.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Clearside Biomedical

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS